Latest news with #VentureMedical
Miami Herald
03-08-2025
- Health
- Miami Herald
Venture Medical Position on CMS and MAC Skin Substitute Proposals
Venture Medical, LCC is sharing our position on the CY2026 Medicare Physician Fee Schedule and our future recommendations. MISSOULA, MT / ACCESS Newswire / August 3, 2025 / The proposed changes to skin substitute reimbursement and coverage in the CY2026 Medicare Physician Fee Schedule (PFS) and Future Effective Local Coverage Determinations (LCDs) are unprecedented and have sparked alarm across the advanced wound care community-particularly among mobile and office-based providers. These proposals, while nominally aimed at consistency and cost control, are based on flawed assumptions and methodologies that will result in reduced access, disrupted clinical practice, and long-term harm to patients and innovation. At Venture Medical we have been working for many months to help chart a course from the current unsustainable system to one which is rational and workable for patients, providers, industry and CMS. As many of you are preparing your comments on these policies, we wanted to share a summary of the direction in which we think the wound care community should be pushing. If you would like to discuss further, please reach out to us. Rescind the Future Effective LCDs Originally designed to control cost-now redundant after CMS pricing product selection harms access, limits clinician choice, and stifles reliance on RCTs ignores the value of real-world evidence (RWE) and other valid harmful for wounds like VLUs, PUs and surgical wounds where RCTs are limited or update cycles span years-unworkable for a dynamic clinical field. Recommendations for the Future: Support Clinical FlexibilityProducts billed "incident to" clinician services should be selected by the clinician like other incident-to are best positioned to select appropriate products based on evidence, experience, and patient new products from the market discourages new product innovation and restricts accessIncentivize evidence development with enhanced payments 8-application cap is not evidence-based and should also be for a National, Uniform LCD FrameworkEstablish consistent rules and documentation standards across all wound regional disparities and overly prescriptive policies-maximize clinical flexibility for ASP Model with a Higher Fixed-Fee RateASP-based pricing is highly variable ($7-$13,117/cm²), unpredictable, and misaligned with clinical reimbursement creates artificial hierarchies not tied to comparative model for 2026: single flat fee (e.g., $600-$1000/cm²) based on economic modelingFix Reimbursement RatesCMS used only HOPD data-other sites of care must be included in rate modeling supports a base rate of $550-$711/cm².Raise non-facility physician application fees to >$500 for equity across care settingsModerate overzealous audit activitySupport Innovation with Evidence-Based EnhancementsEstablish favorable payment enhancements for products which can demonstrate high comparative effectiveness via RCT or RWE - similar to pass-through conceptPush for birth tissue product legislation tied to 2025 Health Services biologics pathway for future tissue products. SOURCE: Venture Medical LLC press release
Miami Herald
07-07-2025
- Business
- Miami Herald
Venture Medical Leads Strategic Investment in Plasmacure to Advance Breakthrough Cold Plasma Technology for Chronic Wound Healing
Venture Medical, LLC, a leader in advanced wound care solutions, today announced the closing of a strategic investment in Plasmacure B.V MISSOULA, MT / ACCESS Newswire / July 7, 2025 / Venture Medical, LLC, a leader in advanced wound care solutions, today announced the closing of a strategic investment in Plasmacure B.V., the Dutch MedTech innovator behind PLASOMA, an award-winning cold plasma therapy for complex wound healing. Venture Medical is leading a €6 million Series A round alongside Coöperatie VGZ, Noaber, Stichting Triade, and existing investors EIC Fund and OostNL. In addition to the direct investment, Venture Medical is also committing over $10 million to support PLASOMA's regulatory approval, reimbursement efforts, and U.S. market expansion. This partnership underscores Venture Medical's ongoing mission to empower providers to deliver healing without boundaries by introducing disruptive technologies that improve patient outcomes and expand access to state-of-the-art care. "As a leading cause of amputations, sepsis, and many other severe complications, chronic wounds impact the lives of millions of patients while presenting a growing burden to our healthcare system," said John Schroeder, CEO of Venture Medical. "We see PLASOMA as a transformative technology that redefines what's possible in wound healing. By investing in Plasmacure and supporting its U.S. rollout, we are enabling clinicians to offer next-generation care that is both innovative and accessible." PLASOMA is a novel wound healing system delivering cold plasma through an intuitively designed pulser and specialized applicator, safely generating plasma from room air directly on the wound surface. Cold plasma has demonstrated powerful antimicrobial effects, while simultaneously promoting tissue regeneration through a variety of other mechanisms. In a recent clinical trial, PLASOMA therapy showed 2.5 times more wound closure than current standards of care. For Venture Medical, the investment is part of a broader commitment to helping healthcare providers access groundbreaking tools across biologics, diagnostics, durable medical equipment, and digital solutions. PLASOMA aligns directly with this vision by offering a scalable, scientifically backed option for treating diabetic foot ulcers, venous leg ulcers, pressure ulcers, and other hard-to-heal wounds. "As our population ages and chronic conditions become more prevalent, the need for effective wound healing solutions grows more urgent," added Schroeder. "With PLASOMA, we're not just treating wounds, we're restoring access, independence, and dignity to patients who've been living without hope." The funding will accelerate Plasmacure's global scale-up while laying the groundwork for U.S. FDA clearance, payer access, and national distribution through Venture Medical's extensive provider network. "We are deeply motivated by the needs of the millions living with hard-to-heal wounds," said Bjorn Sprengers, CEO of Plasmacure. "With this investment and our new strategic partners, we are in a strong position to bring PLASOMA to more patients worldwide." About Venture Medical, LLCVenture Medical is a U.S.-based healthcare services company specializing in advanced wound care. As a master distributor and digital solutions partner, Venture Medical equips clinicians with breakthrough biologics, diagnostics, and capital equipment to improve patient outcomes across care settings. Learn more at About Plasmacure in 2014 in the Netherlands, Plasmacure is the developer of PLASOMA, a cold plasma therapy designed to accelerate healing in chronic wounds. The company aims to revolutionize wound care through safe, effective, and scalable technology. Visit to learn more. SOURCE: Venture Medical LLC press release
Associated Press
11-06-2025
- Business
- Associated Press
Venture Medical Announces Acquisition of Certain Assets of ProgenaCare Global to Expand Advanced Wound Care Portfolio
MISSOULA, MONTANA / ACCESS Newswire / June 11, 2025 / Venture Medical, LLC, a leader in wound care solutions, today announced its acquisition of certain assets of ProgenaCare Global, LLC, a biotechnology company known for its innovative, keratin-based wound healing technologies, including ProgenaMatrix® and intellectual property underlying an expected future product line. This acquisition marks a significant milestone in Venture Medical's mission to deliver clinically proven, accessible, and ethically grounded wound care solutions to providers across the country. By integrating ProgenaCare's proprietary keratin platform, Venture Medical enhances its advanced therapy portfolio with regenerative technologies that accelerate healing and improve outcomes for patients with chronic and hard-to-heal wounds. Howard Walthall, former CEO of ProgenaCare, has also joined Venture Medical as Senior Vice President of Product Development. 'Venture Medical is at the forefront of patient-centered innovation. Between their comprehensive product formulary and proprietary Venture OneView platform, they are positioned to become a nationwide leader in the wound care space,' said Bert Jones, Chairman of the Board of ProgenaCare Global. 'We are excited to see our mission continue with a company that shares our values and has the infrastructure to scale our impact.' 'ProgenaCare has long stood for integrity, science, and healing - all values that align seamlessly with Venture Medical,' said John Schroeder, CEO of Venture Medical. 'With Howard Walthall on board and these technologies in our portfolio, we're positioned to elevate the standard of care and improve patient outcomes in ways that are both clinically meaningful and beneficial to the industry as a whole.' The acquisition includes full rights to ProgenaMatrix®, the first and only keratin matrix cleared by the FDA for wound management, and contractual rights to distribute revyve™, an advanced antimicrobial hydrogel. Both products are now available through Venture Medical's extensive distribution network. About Venture Medical, LLC: Venture Medical is a groundbreaking healthcare services company with a decade-long history of innovation, dedication, and consistent growth in the field of wound care and healing. Over the past 15 years, Venture Medical has expanded its reach across the United States and has grown to become a leading commercial partner and software services provider for manufacturers and end users of biologics, advanced diagnostics, durable medical equipment, and capital goods. About ProgenaCare Global, LLC: ProgenaCare Global is a biotechnology company focused on developing keratin-based regenerative therapies. Its core technologies are designed to accelerate tissue regeneration, reduce inflammation, and promote healthy wound closure with biocompatible and biologically active materials. Contact Information Carey Brandenburg Director of Marketing & Communications [email protected] 800-881-1809 SOURCE: Venture Medical LLC press release
